203 related articles for article (PubMed ID: 36124593)
1. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
2. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
3. A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence.
Xing Q; Liu S; Luan J; Wang Y; Ma L
Pathol Res Pract; 2021 Sep; 225():153587. PubMed ID: 34419719
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
6. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
7. Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer.
Liu B; Li X; Li J; Jin H; Jia H; Ge X
Dis Markers; 2020; 2020():8860788. PubMed ID: 33101546
[TBL] [Abstract][Full Text] [Related]
8. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
[TBL] [Abstract][Full Text] [Related]
10. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
[TBL] [Abstract][Full Text] [Related]
11. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J
Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418
[TBL] [Abstract][Full Text] [Related]
12. A Novel Set of Immune-associated Gene Signature predicts Biochemical Recurrence in Localized Prostate Cancer Patients after Radical Prostatectomy.
Luan JC; Zhang QJ; Zhao K; Zhou X; Yao LY; Zhang TT; Zeng TY; Xia JD; Song NH
J Cancer; 2021; 12(12):3715-3725. PubMed ID: 33995646
[No Abstract] [Full Text] [Related]
13. A N
Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
[TBL] [Abstract][Full Text] [Related]
14. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
15. Identification and Validation of a Prognostic 5-Protein Signature for Biochemical Recurrence Following Radical Prostatectomy for Prostate Cancer.
Lv D; Cao Z; Li W; Zheng H; Wu X; Liu Y; Gu D; Zeng G
Front Surg; 2021; 8():665115. PubMed ID: 34136527
[No Abstract] [Full Text] [Related]
16. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
Jin Y; Wang L; Lou H; Song C; He X; Ding M
Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
[TBL] [Abstract][Full Text] [Related]
17. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.
Zhao Y; Tao Z; Li L; Zheng J; Chen X
BMC Cancer; 2022 Mar; 22(1):239. PubMed ID: 35246070
[TBL] [Abstract][Full Text] [Related]
18. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.
Liu W; Wang M; Wang M; Liu M
Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899
[TBL] [Abstract][Full Text] [Related]
19. A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer.
Hu D; Cao Q; Tong M; Ji C; Li Z; Huang W; Jin Y; Tong G; Wang Y; Li P; Zhang H
BMC Med Genomics; 2022 Feb; 15(1):24. PubMed ID: 35135561
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of a signature involving voltage-gated chloride ion channel genes for prediction of prostate cancer recurrence.
Luo Y; Liu X; Li X; Zhong W; Lin J; Chen Q
Front Endocrinol (Lausanne); 2022; 13():1001634. PubMed ID: 36246902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
